Highlight Therapeutics looks to boost the power and reach of immuno-oncology drugs
BO-112, the first spanish immunotherapy has completed the first research phase in patients with immunotherapy-resistant cancer - Biotech Spain
Highlight Therapeutics present developments for lead drug candidate BO-112 in patients with melanoma - YouTube
Highlight Therapeutics y Pivotal trabajan conjuntamente en el tratamiento del melanoma y lanzan un ensayo clínico fase IIa para determinar la seguridad y eficacia de BO-112
Classes — Highlight Therapeutics
Classes — Highlight Therapeutics
BO-112, el primer fármaco español que mejora la eficacia de la inmunoterapia en pacientes con cáncer | Salud
Una nueva combinación de inmunoterapia permite erradicar lesiones tumorales en modelos animales
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors | Science Translational Medicine
La valenciana Highlight Therapeutics cierra una ronda de 22,6 millones para terapias oncológicas - Fundación Conexus
Classes — Highlight Therapeutics
Highlight Therapeutics & Pivotal colaboran de nuevo en un ensayo fase IIa en tumores Gastro-Intestinales
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control | Journal for ImmunoTherapy of Cancer
Our Instructors — Highlight Therapeutics
SITC 2021: Highlight Therapeutics' BO-112 boosts checkpoint response rate in phase II | 2021-11-12 | BioWorld
Classes — Highlight Therapeutics
Highlight Therapeutics levanta una Ronda para el desarrollo clínico phase 2 de su terapia inmuno-oncología en diferentes tipos tumorales con la participación de Columbus Venture Partners, Advent Life Science y el CDTI | #
Highlight Therapeutics announces follow-up results from Phase 2b study of BO -112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR | AseBio - Asociación Española de Biotecnología
Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis Madrid, Spain - June 26, 2020: Highl
Classes — Highlight Therapeutics
Highlight Therapeutics - Crunchbase Company Profile & Funding
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors | Science Translational Medicine
Quibim se asocia con Highlight Therapeutics para avanzar en la inmunoterapia del melanoma - Bioval
Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO- 112 + STING agonist published
SITC 2021: Highlight Therapeutics' BO-112 boosts checkpoint response rate in phase II | 2021-11-12 | BioWorld
HIGHLIGHT THERAPEUTICS
Our Instructors — Highlight Therapeutics
